伊立替康联合奈达铂治疗复发耐药晚期上皮性卵巢癌的疗效研究

伊立替康联合奈达铂治疗复发耐药晚期上皮性卵巢癌的疗效研
究
康马飞;卜庆;刘瑛;骆梅青;廖漓漓;涂江江
【期刊名称】《中国全科医学》
【年(卷),期】2011(014)033
【摘要】目的探讨伊立替康(IRI)联合奈达铂(NDP)治疗复发耐药的晚期上皮性卵巢癌的疗效和毒副作用.方法选择对一线及二线方案耐药的复发晚期上皮性卵巢癌42例,随机分为IRI组和IRI+NDP组,每组21例.IRI组第1、8天给予IRI 125 mg/m2,每21 d重复1次;IRI+NDP组第1、8 天给予IRI 125 mg/m2,第1天给予NDP 80 mg/m2,每21 d重复1次,比较两组的疗效及毒副作用.结果 IRI+NDP 组:完全缓解(CR)1例,部分缓解(PR)10例,稳定(SD)4例,进展(PD)6例,总有效率(ORR)为52.4%;中位肿瘤进展时间(mTTP)(4.5±0.6)个月.IRI组:PR 4例,SD 7例,PD 10例,ORR为19.0%;mTTP(3.2±0.3)个月.两组疗效比较,差异有统计学意义(P＜0.05).两组mTTP比较,差异有统计学意义(P＜0.05).粒细胞减少发生率
IRI+NDP组高于IRI组,差异有统计学意义(P＜0.05).结论 IRI联合NDP三线药治疗复发晚期上皮性卵巢癌的疗效较单用IRI高,患者耐受性好.%Objective To investigate the efficacy and side effects of irinotecan ( IRI ) combined with nedaplatin in the third line treatment of recurrent and drug resistant advanced epithelial ovarian carcinoma. Methods Forty - two patients with recurrent and refractory ( resistant to first and second line drugs ) advanced epithelial ovarian carcinoma were divided randomly into the IRI group ( irinotecan alone ) and the IRI - NDP group ( irinotecan combined
with nedaplatin ), with 21 cases in each group. For the IRI group, IRI ( 125 mg/m ) was administered on day 1 and day 8 , and then repeated every 21 days; for the IRI- NDP group, IRI ( 125 mg/m2 ) was administered on day 1 and day 8, with NDP ( 80 mg/m2 ) administered on day 1, and then repeated every 21 days. Efficacy and adverse reactions were compared between the two groups. Results Numbers of complete response ( CR ), partial response ( PR ), stable disease ( SD ) and progress disease ( PD ) cases were 1, 10, 4 and 6 respectively in the IRI-NDP group, with an overall response rate ( ORR ) of 52. 4% and a median time to progress ( mTTP ) of ( 4. 5± 0. 6 ) months; numbers of PR, SD and PD cases were 4, 7 and 10 respectively in the IRI group, with an ORR of 19. 0% and an mTTP of ( 3. 2 ± 0. 3 ) months. Both efficacy and mTTP were significantly different between the two groups ( all P < 0. 05 ) . Incidence rate of granulocytopenia was higher in the IRI - NDP group than in the IRI group ( P < 0. 05 ) . Conclusion Irinotecan combined with nedaplatin displays higher response rate in treating recurrent and drug resistant advanced epithelial ovarian carcinoma than irinotecan used alone and is well tolerated.
【总页数】2页(P3859-3860)
【作者】康马飞;卜庆;刘瑛;骆梅青;廖漓漓;涂江江
【作者单位】541001,广西桂林市,桂林医学院附属医院肿瘤内科;541001,广西桂林市,桂林医学院附属医院肿瘤内科;541001,广西桂林市,桂林医学院附属医院肿瘤内
科;541001,广西桂林市,桂林医学院附属医院肿瘤内科;541001,广西桂林市,桂林医学院附属医院肿瘤内科;541001,广西桂林市,桂林医学院附属医院肿瘤内科
【正文语种】中文
【中图分类】R737.31
【相关文献】
1.伊立替康联合奈达铂治疗复发性上皮性卵巢癌的安全性及疗效研究 [J], 闵慜;王巧红;狄文;马忠妹;吴霞
2.伊立替康联合奈达铂治疗复发耐药晚期上皮卵巢癌的疗效和毒副作用 [J], 张素萍;周冰侠;王杏芹
3.培美曲塞二钠联合奈达铂治疗复发晚期上皮性卵巢癌的效果分析 [J], 杨秀丽
4.伊立替康联合奈达铂治疗复发的晚期食管癌 [J], 汪竹;童建东;袁昕;韩芳
5.培美曲塞联合奈达铂治疗复发晚期上皮性卵巢癌的疗效观察 [J], 邓文静;林秀欣;周颖
因版权原因，仅展示原文概要，查看原文内容请购买。